Research ExplorerPublicationsOccurrence and characteristics of patients with de novo adva...

Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry

Standard

Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry. / Müller, Volkmar; Hein, Alexander; Hartkopf, Andreas D; Fasching, Peter A; Kolberg, Hans-Christian; Hadji, Peyman; Tesch, Hans; Häberle, Lothar; Ettl, Johannes; Lüftner, Diana; Wallwiener, Markus; Beckmann, Matthias W; Schneeweiss, Andreas; Belleville, Erik; Uhrig, Sabrina; Wimberger, Pauline; Hielscher, Carsten; Meyer, Julia; Wurmthaler, Lena A; Kurbacher, Christian M; Wuerstlein, Rachel; Untch, Michael; Janni, Wolfgang; Taran, Florin-Andrei; Lux, Michael P; Wallwiener, Diethelm; Brucker, Sara Y; Fehm, Tanja N; Michel, Laura L.

In: EUR J CANCER, Vol. 172, 09.2022, p. 13-21.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Müller, V, Hein, A, Hartkopf, AD, Fasching, PA, Kolberg, H-C, Hadji, P, Tesch, H, Häberle, L, Ettl, J, Lüftner, D, Wallwiener, M, Beckmann, MW, Schneeweiss, A, Belleville, E, Uhrig, S, Wimberger, P, Hielscher, C, Meyer, J, Wurmthaler, LA, Kurbacher, CM, Wuerstlein, R, Untch, M, Janni, W, Taran, F-A, Lux, MP, Wallwiener, D, Brucker, SY, Fehm, TN & Michel, LL 2022, 'Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry', EUR J CANCER, vol. 172, pp. 13-21. https://doi.org/10.1016/j.ejca.2022.05.015

APA

Müller, V., Hein, A., Hartkopf, A. D., Fasching, P. A., Kolberg, H-C., Hadji, P., Tesch, H., Häberle, L., Ettl, J., Lüftner, D., Wallwiener, M., Beckmann, M. W., Schneeweiss, A., Belleville, E., Uhrig, S., Wimberger, P., Hielscher, C., Meyer, J., Wurmthaler, L. A., ... Michel, L. L. (2022). Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry. EUR J CANCER, 172, 13-21. https://doi.org/10.1016/j.ejca.2022.05.015

Vancouver

Müller V, Hein A, Hartkopf AD, Fasching PA, Kolberg H-C, Hadji P et al. Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry. EUR J CANCER. 2022 Sep;172:13-21. https://doi.org/10.1016/j.ejca.2022.05.015

Bibtex

@article{575df46215c2464897ae1ca442a52bb2,
title = "Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry",
abstract = "BACKGROUND: Patients with de novo metastatic breast cancer (dnMBC) may have different clinical and pathological characteristics. In studies concerned with first-line metastatic patients, the proportion of these patients without secondary resistance mechanisms may have a large influence ont the study results. The aim of this study was to identify patient and tumor characteristics that are associated with dnMBC vs. recurrent MBC (rMBC).METHODS: This is a retrospective analysis of data prospectively collected in the PRAEGNANT metastatic breast cancer registry (NCT02338167). Firs line treated patients were eligible. Patient and tumor characteristics were compared with common disease and tumor characteristics relative to de novo metastatic status, as well as early and late recurrences after primary disease without metastases.RESULTS: Among the 947 patients identified, 355 were included with de novo metastatic disease (37.5%). Older age and HER2-positive disease were significantly associated with a higher frequency of dnMBC. Patients younger than 50, 50-69, or 70 years or older had dnMBC frequencies of 22.7%, 44.0%, and 57.6%, respectively. HER2-positive patients had dnMBC at initial presentation in 49.1% of cases, in comparison with 21.9%, 35.5%, and 37.6% in patients with triple-negative, luminal A-like and luminal B-like breast cancer, respectively.CONCLUSION: Age and breast cancer subtype are associated with the frequency of first-line MBC patients. Inclusion criteria concerning age or breast cancer subtype can influence the frequency of these patients in a selected patient population and can therefore modify the number of patients with secondary resistance to specific therapies in clinical trials.",
keywords = "Breast Neoplasms/drug therapy, Clinical Studies as Topic, Female, Humans, Neoplasm Recurrence, Local/pathology, Prognosis, Receptor, ErbB-2, Registries, Retrospective Studies",
author = "Volkmar M{\"u}ller and Alexander Hein and Hartkopf, {Andreas D} and Fasching, {Peter A} and Hans-Christian Kolberg and Peyman Hadji and Hans Tesch and Lothar H{\"a}berle and Johannes Ettl and Diana L{\"u}ftner and Markus Wallwiener and Beckmann, {Matthias W} and Andreas Schneeweiss and Erik Belleville and Sabrina Uhrig and Pauline Wimberger and Carsten Hielscher and Julia Meyer and Wurmthaler, {Lena A} and Kurbacher, {Christian M} and Rachel Wuerstlein and Michael Untch and Wolfgang Janni and Florin-Andrei Taran and Lux, {Michael P} and Diethelm Wallwiener and Brucker, {Sara Y} and Fehm, {Tanja N} and Michel, {Laura L}",
note = "Copyright {\textcopyright} 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.",
year = "2022",
month = sep,
doi = "10.1016/j.ejca.2022.05.015",
language = "English",
volume = "172",
pages = "13--21",
journal = "EUR J CANCER",
issn = "0959-8049",
publisher = "Elsevier Limited",

}

RIS

TY - JOUR

T1 - Occurrence and characteristics of patients with de novo advanced breast cancer according to patient and tumor characteristics - A retrospective analysis of a real world registry

AU - Müller, Volkmar

AU - Hein, Alexander

AU - Hartkopf, Andreas D

AU - Fasching, Peter A

AU - Kolberg, Hans-Christian

AU - Hadji, Peyman

AU - Tesch, Hans

AU - Häberle, Lothar

AU - Ettl, Johannes

AU - Lüftner, Diana

AU - Wallwiener, Markus

AU - Beckmann, Matthias W

AU - Schneeweiss, Andreas

AU - Belleville, Erik

AU - Uhrig, Sabrina

AU - Wimberger, Pauline

AU - Hielscher, Carsten

AU - Meyer, Julia

AU - Wurmthaler, Lena A

AU - Kurbacher, Christian M

AU - Wuerstlein, Rachel

AU - Untch, Michael

AU - Janni, Wolfgang

AU - Taran, Florin-Andrei

AU - Lux, Michael P

AU - Wallwiener, Diethelm

AU - Brucker, Sara Y

AU - Fehm, Tanja N

AU - Michel, Laura L

N1 - Copyright © 2022 The Authors. Published by Elsevier Ltd.. All rights reserved.

PY - 2022/9

Y1 - 2022/9

N2 - BACKGROUND: Patients with de novo metastatic breast cancer (dnMBC) may have different clinical and pathological characteristics. In studies concerned with first-line metastatic patients, the proportion of these patients without secondary resistance mechanisms may have a large influence ont the study results. The aim of this study was to identify patient and tumor characteristics that are associated with dnMBC vs. recurrent MBC (rMBC).METHODS: This is a retrospective analysis of data prospectively collected in the PRAEGNANT metastatic breast cancer registry (NCT02338167). Firs line treated patients were eligible. Patient and tumor characteristics were compared with common disease and tumor characteristics relative to de novo metastatic status, as well as early and late recurrences after primary disease without metastases.RESULTS: Among the 947 patients identified, 355 were included with de novo metastatic disease (37.5%). Older age and HER2-positive disease were significantly associated with a higher frequency of dnMBC. Patients younger than 50, 50-69, or 70 years or older had dnMBC frequencies of 22.7%, 44.0%, and 57.6%, respectively. HER2-positive patients had dnMBC at initial presentation in 49.1% of cases, in comparison with 21.9%, 35.5%, and 37.6% in patients with triple-negative, luminal A-like and luminal B-like breast cancer, respectively.CONCLUSION: Age and breast cancer subtype are associated with the frequency of first-line MBC patients. Inclusion criteria concerning age or breast cancer subtype can influence the frequency of these patients in a selected patient population and can therefore modify the number of patients with secondary resistance to specific therapies in clinical trials.

AB - BACKGROUND: Patients with de novo metastatic breast cancer (dnMBC) may have different clinical and pathological characteristics. In studies concerned with first-line metastatic patients, the proportion of these patients without secondary resistance mechanisms may have a large influence ont the study results. The aim of this study was to identify patient and tumor characteristics that are associated with dnMBC vs. recurrent MBC (rMBC).METHODS: This is a retrospective analysis of data prospectively collected in the PRAEGNANT metastatic breast cancer registry (NCT02338167). Firs line treated patients were eligible. Patient and tumor characteristics were compared with common disease and tumor characteristics relative to de novo metastatic status, as well as early and late recurrences after primary disease without metastases.RESULTS: Among the 947 patients identified, 355 were included with de novo metastatic disease (37.5%). Older age and HER2-positive disease were significantly associated with a higher frequency of dnMBC. Patients younger than 50, 50-69, or 70 years or older had dnMBC frequencies of 22.7%, 44.0%, and 57.6%, respectively. HER2-positive patients had dnMBC at initial presentation in 49.1% of cases, in comparison with 21.9%, 35.5%, and 37.6% in patients with triple-negative, luminal A-like and luminal B-like breast cancer, respectively.CONCLUSION: Age and breast cancer subtype are associated with the frequency of first-line MBC patients. Inclusion criteria concerning age or breast cancer subtype can influence the frequency of these patients in a selected patient population and can therefore modify the number of patients with secondary resistance to specific therapies in clinical trials.

KW - Breast Neoplasms/drug therapy

KW - Clinical Studies as Topic

KW - Female

KW - Humans

KW - Neoplasm Recurrence, Local/pathology

KW - Prognosis

KW - Receptor, ErbB-2

KW - Registries

KW - Retrospective Studies

U2 - 10.1016/j.ejca.2022.05.015

DO - 10.1016/j.ejca.2022.05.015

M3 - SCORING: Journal article

C2 - 35728342

VL - 172

SP - 13

EP - 21

JO - EUR J CANCER

JF - EUR J CANCER

SN - 0959-8049

ER -